Day: September 14, 2016

Evine Secures Strategic Investment Led By Tommy Hilfiger, Morris Goldfarb and Tommy Mottola

MINNEAPOLIS, Sept. 14, 2016 (GLOBE NEWSWIRE) — Evine Live Inc. (NASDAQ:EVLV) (“Evine” or the “Company”) announced today the execution of a definitive agreement to sell $10 million of common stock at $1.68 per share, which was priced at a 10 percent discount to the previous 15 day average of the Company’s stock, to investors (“Investors”) that include, among others, Mr. Tommy Hilfiger, Mr. Morris Goldfarb and Mr. Tommy Mottola. This initial investment is expected to close within a week. In connection with this investment, the Company also announced that Tommy Hilfiger and Tommy Mottola will become advisors to Evine. Bob

Agios Announces Pricing of $150 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Sept. 14, 2016 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced that it has priced an underwritten public offering of 3,370,786 shares of common stock at a price to the public of $44.50 per share, before underwriting discounts, which would result in aggregate gross proceeds of approximately $150 million. All of the shares in the offering are to be sold by Agios. Agios has also granted the underwriters a 30-day option to purchase up to an additional 505,617 shares of common stock on the same terms and conditions. Closing of the offering is expected to occur on

Nova LifeStyle Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LOS ANGELES, Sept. 14, 2016 (GLOBE NEWSWIRE) — Nova LifeStyle, Inc. (NASDAQ:NVFY) (“Nova LifeStyle” or the “Company”), a U.S.-based, leading innovative designer, manufacturer and distributor of modern life style furniture, today announced that on May 18, 2016 the Company entered into employment agreements with three designers (Mr. Xie Bin, Mr. Yang Xing and Ms. E Zhao) pursuant to which the Company agreed to issue 120,000 restricted shares per year to each of the designers. The employment agreements with the three new employees each have a two-year term. The awards were made pursuant to the NASDAQ inducement grant exception as a component of

Feature Box

MCBC Holdings, Inc. Announces Pricing of Follow-on Offering

VONORE, Tenn., Sept. 14, 2016 (GLOBE NEWSWIRE) — MCBC Holdings, Inc. (NASDAQ:MCFT) (the “Company”) today announced the pricing of a secondary offering (the “Offering”) of 4,000,000 shares of its common stock held by affiliates of Wayzata Investment Partners at a public offering price of $10.25 per share.  In addition, the selling stockholder has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of the Company’s common stock at the public offering price, less the underwriting discount.  No shares are being sold by the Company in the Offering, and the Company will not receive any proceeds from

Feature Box

Huntington Ingalls Industries Selected To Perform Overhaul Work On USS Ramage (DDG 61)

PASCAGOULA, Miss., Sept. 14, 2016 (GLOBE NEWSWIRE) — Huntington Ingalls Industries’ (NYSE:HII) Ingalls Shipbuilding division has been awarded a $14 million base contract to perform an extended selected restricted availability on the Arleigh Burke-class (DDG 51) destroyer USS Ramage (DDG 61). With all options exercised, the total contract value would be $21.4 million. USS Ramage was originally built at Ingalls and delivered to the U.S. Navy in 1995. “Ingalls has a longstanding tradition in the overhaul/modernization business,” said Ingalls Shipbuilding President Brian Cuccias. “We are pleased with the Navy’s confidence in us to perform this work on DDG 61. It

El Pollo Loco Celebrates National Chicken Month with Special Offers

COSTA MESA, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) — Calling all chicken enthusiasts! El Pollo Loco (Nasdaq:LOCO), the nation’s leading fire-grilled chicken chain, is celebrating National Chicken Month with exciting promotions for guests now through September 30. In honor of the most delicious month of the year, El Pollo Loco is offering special deals that are sure to delight chicken fans. Throughout the month of September, guests who spend $10 will receive a coupon for a $5 2-piece leg and thigh combo meal on their next visit. The Company is also offering $1 off coupons to fans who show their

DNB Financial Corporation Receives All Required Approvals to Acquire East River Bank

DOWNINGTOWN, Pa., Sept. 14, 2016 (GLOBE NEWSWIRE) — DNB Financial Corporation (“DNB”) (NASDAQ:DNBF), the parent company of DNB First, National Association, today announced that it has obtained all required approvals necessary for DNB to consummate its acquisition of East River Bank, Philadelphia, Pennsylvania (“East River”). Approvals included DNB and East River shareholder approvals, and regulatory approval from the Office of the Comptroller of the Currency, the Board of Governors of the Federal Reserve System and the Pennsylvania Department of Banking. When the combination of the two organizations is completed, DNB will have approximately $1.1 billion in assets, $764 million in

Retrophin to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series

SAN DIEGO, Sept. 14, 2016 (GLOBE NEWSWIRE) — Retrophin, Inc. (Nasdaq:RTRX) today announced that Alvin Shih, M.D., executive vice president and head of research & development, will present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series in New York City on Wednesday, September 28, 2016 at 11:05 a.m. ET. A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and an archived replay will be accessible for up to 90 days.            About Retrophin Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s

Nevada Gold & Casinos Reports First Quarter 2017 Financial Results

LAS VEGAS, Sept. 14, 2016 (GLOBE NEWSWIRE) — Nevada Gold & Casinos, Inc. (NYSE MKT:UWN) today announced financial results for the first quarter ended July 31, 2016. For the first quarter of fiscal 2017, the company reported net revenues of $18.3 million compared to $15.9 million in the first quarter of fiscal 2016. Operating expenses were $18.2 million compared to $15.2 million in the prior year period.  Operating income was $0.1 million compared to $0.8 million and net loss was $0.1 million, or $0.01 loss per share, compared to net income of $0.5 million, or $0.03 per share, in the

Student Transportation Inc. Reports Fourth Quarter & Fiscal Year 2016 Results

BARRIE, Ontario, Sept. 14, 2016 (GLOBE NEWSWIRE) — Student Transportation Inc. (TSX:STB) (NASDAQ:STB) (“STI” or “the Company”) today announced financial results for the fourth quarter and fiscal year ended June 30, 2016. All financial results are reported in U.S. dollars except as otherwise noted. “We were very pleased with our strong performance and solid results in fiscal 2016 which were in line with our internal objectives and we are well-positioned for continued improvements in fiscal 2017,” said Denis J. Gallagher, STI Chairman and CEO. “Our year-end results reflect the positive impact of our fuel management and early stage returns from strategic

Globe Newswire

Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2016 Financial Results

ATLANTA, Sept. 14, 2016 (GLOBE NEWSWIRE) — Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the fourth quarter and 2016 fiscal year ended June 30, 2016, and also provided an update on recent corporate and clinical developments. “Over the last twelve months we have made significant advances with our three next generation direct-acting antivirals that address serious infections with limited therapeutic options. Enrollment is 90% complete in the SPIRITUS Phase 2b trial of vapendavir for the treatment of human rhinovirus infections in moderate and severe asthmatic patients, and we look forward to announcing top-line data from the trial

Proteostasis Therapeutics Announces Closing of Follow-On Public Offering of Common Stock

CAMBRIDGE, Mass., Sept. 14, 2016 (GLOBE NEWSWIRE) — Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis, today announced the closing of its follow-on public offering of 5,000,000 shares of its common stock at a public offering price of $13.00 per share, before the underwriting discount. All of the shares sold were offered by Proteostasis Therapeutics, Inc. The gross proceeds from the offering are $65 million, before deducting the underwriting discount and expenses associated with the offering payable by the company. In addition, the company has granted

Feature Box

Aspen Group Reports 62% Increase in Revenue for First Quarter Fiscal 2017, Gross Margin Increases 1,500 Basis Points

NEW YORK, Sept. 14, 2016 (GLOBE NEWSWIRE) — Aspen Group, Inc. (OTCQB:ASPU) (“Aspen”), a nationally accredited online post-secondary education company (Aspen University), today announced financial results for its 2017 fiscal first quarter ended July 31, 2016. The Company will host a conference call to discuss its financial results on Wednesday, September 14, 2016, at 5:00 p.m. (ET).  “Aspen just recorded its highest enrollment quarter in the company’s history, all during our seasonally slowest summer period, which is a testament to the strength of our ‘pay-as-you-go,’ debtless education business model.  Our conversion rate increased to a record 11.2% in the quarter

Global Blood Therapeutics Announces Publication of Preclinical Results Supporting GBT440 Program for Hypoxemic Pulmonary Disorders

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today announced publication of preclinical data supporting the development of GBT440 for the treatment of hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis (IPF), in Physiological Reports. To date, GBT has established preclinical proof of concept for GBT1118, a hemoglobin modifier and analog of GBT440, in three different animal models of hypoxia. Data from these models support the potential beneficial effects of hemoglobin modification as a promising therapeutic strategy

Apigee Announces Fourth Quarter and Fiscal 2016 Results

SAN JOSE, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) — Apigee® (NASDAQ:APIC), the API company, today announced financial results for its fourth quarter and fiscal year ended July 31, 2016. Fiscal Year 2016 For FY 16, Apigee reported total revenue of $92.0 million, up 34% compared to $68.6 million in FY 15.  Apigee reported FY 16 product revenue (defined as license revenue plus subscription and support revenue) of $75.3 million, up 46% compared to $51.6 million in FY 15. Apigee reported FY 16 GAAP gross margin of 70.1%, up from 63.6% in FY 15, and non-GAAP gross margin of 71.8% compared to

Immune Design Announces Proposed Public Offering of Common Stock

SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) — Immune Design Corp. (Nasdaq:IMDZ) announced today that it plans to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the proposed offering are to be sold by Immune Design. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Jefferies LLC, Leerink Partners LLC and Wells Fargo Securities, LLC are acting as joint book-running managers for the

Builders FirstSource, Inc. Announces Modified Dutch Auction Tender Offer for 10.75% Senior Notes Due 2023

DALLAS, Sept. 14, 2016 (GLOBE NEWSWIRE) — Builders FirstSource, Inc. (the “Company”) (Nasdaq:BLDR), a leading supplier and manufacturer of structural and related building products for residential new construction and home repair and remodeling in the United States, today announced the commencement of a cash tender offer to purchase (the “Tender Offer”) up to $50,000,000 aggregate principal amount of its 10.75% Senior Notes due 2023 (CUSIP Nos. 12008R AH0 (144A) and U08985 AD2 (Reg S)) (the “Notes”) at a purchase price per $1,000 principal amount determined in accordance with a modified Dutch auction procedure on the terms and subject to the

Frequency Electronics, Inc. Announces First Quarter Fiscal Year 2017 Results

MITCHEL FIELD, N.Y., Sept. 14, 2016 (GLOBE NEWSWIRE) — Frequency Electronics, Inc. (NASDAQ:FEIM) reported revenues for the first quarter of fiscal 2017, which ended July 31, 2016, of $12.7 million as compared to $16.7 million in the same quarter of fiscal 2016.  The Company recorded operating loss of $796,000 for the quarter ended July 31, 2016, compared to an operating profit of $941,000 in the first quarter of fiscal 2016.  Net loss for the first quarter of fiscal 2017 was $706,000 or ($0.08) per diluted share compared to net income of $891,000 or $0.10 per diluted share for the first

U.S. Global Investors Reports Financial Results for Fiscal Year 2016

San Antonio, TX, Sept. 14, 2016 (GLOBE NEWSWIRE) — For Immediate Release U.S. Global Investors Reports Financial Results for Fiscal Year 2016 Continuing Dividends and Share Repurchase Program ************************************************************************ SAN ANTONIO-September 14, 2016 –U.S. Global Investors, Inc. (NASDAQ: GROW), a boutique registered investment advisory firm with longstanding experience in global markets and specialized sectors, today reported a net loss of $3.7 million, or $(0.24) per share, on operating revenues of $5.5 million for the fiscal year ended June 30, 2016. For the fiscal year 2015, U.S. Global Investors recorded a net loss of $4.0 million, or $(0.26) per share, on

Vitamin absorption and deficiency detection pivotal to sustained growth in Global Multivitamin Market

SAN ANTONIO, Sept. 14, 2016 (GLOBE NEWSWIRE) — Verify Markets’ analysis of The Status of the Global Multivitamin Market shows that the market is valued at over $10 billion in sales for 2015 (http://www.verifymarkets.com/products/2016-global-multivitamin-market).  The global market for multivitamins is both fragmented and at a point of stagnation, growing slowly. Despite this, multivitamins are used more frequently and more often than other vitamins or dietary supplements, globally. The major market drivers for the multivitamin market include increased multinational company participation in the category, rising economic confidence and an enormous and fast-emerging middle class in several large countries (Brazil, Russia, India and